Our licensing opportunities tagged with Medical Therapeutics are shown below.
Humanised anti-CD4 monoclonal antibody to prevent antigen-specific immunological responses to life-saving therapeutic proteins. Proof of mechanism has been demonstrated preclinically and in man.
Bulk acoustic wave (BAW) sensors based on micromechanical systems (MEMS) offer significant advantages over quartz crystal microbalance (QCM); such as compact size, compatibility with electronics, lower power consumption, lower cost and higher reliability. However, their wide application to real-world detection remains limited by the temperature-dependence of their performance. Recently researchers at the University of Cambridge have developed a novel Film Bulk Acoustic Resonator (FBAR) device which has the potential to overcome this limitation by enabling the simultaneous measurement of temperature and mass loading in a single device without increasing their size or adding complexity to the electronics. Through the use of a novel multi-layer device structure and electrode materials, temperature self-referenced FBAR resonators with high operating frequencies (~1-2 GHz) and world-leading Q-factors (>1500) have been produced paving the way for real-world monitoring using FBAR sensors.
Key potential benefits:
Parallel sensing of several physical variables within the same unit sensor
Small size (around 150μm × 150μm)
Ultrahigh sensitivity ( in range of 10-14 to 10-15g)
Tuneable frequency of actuation (suitable for >1 GHz applications)
A viral CD30 polypeptide that may be used to treat inflammatory diseases for example autoimmune diseases, rheumatoid arthritis, systemic lupus erythematosus or multiple sclerosis. Viral CD30 works in the same way as human CD30 antibodies to neutralise interactions between CD30 ligand and its receptor but may have additional effects to CD30 antibodies by inducing signalling in cells expressing CD30 ligand.
A method of identifying and eliminating human cytomegalovirus infected cells from bone marrow transplants. This technology has the potential to increase survival rates of transplant recipients and to reduce disease complications in transplant recipients.
Administration of a recombinant protein known to be involved in preventing oxidative stress to preterm infants shortly after birth is therapeutically beneficial to protect against complications of prematurity and to reduce the costs of neonatal intensive case.
A novel drug-like series of 5-HT1B antagonists with excellent potential for treatment of pulmonary arterial hypertension (PAH) with a low side effect profile and in-vivo data showing reversal of PAH.
Novel, improved, human, antibody constant regions which lack destructive effector functions. These constant regions can be combined with the variable region genes or receptor domains of your choice to produce antibodies or fusion proteins of any desired specificity. Specific applications in the areas of autoimmunity, inflammation, allergy, asthma and cardiovascular disease are envisaged.